STOCK TITAN
  1. Home
  2. News
  3. SPRC

SciSparc Ltd. Ordinary Shares - $SPRC STOCK NEWS

Welcome to our dedicated page for SciSparc Ltd. Ordinary Shares news (Ticker: $SPRC), a resource for investors and traders seeking the latest updates and insights on SciSparc Ltd. Ordinary Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SciSparc Ltd. Ordinary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SciSparc Ltd. Ordinary Shares's position in the market.

News
SciSparc Granted European Patent for its Core Technology
Rhea-AI Summary
SciSparc Ltd. has been granted a new patent for combinations of cannabinoids and N-Acylethanolamines, solidifying its position as a leader in the cannabis space. The patent aligns with the company's objective to increase the safety of cannabinoids treatments while maintaining their therapeutic effects. This grant expands the company's intellectual property portfolio worldwide and supports its innovation in cannabis technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.59%
Tags
none
-
News
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
Rhea-AI Summary
SciSparc initiates pivotal clinical trial for drug candidate SCI-210 to treat Autism Spectrum Disorder (ASD)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.16%
Tags
clinical trial
-
News
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
Rhea-AI Summary
SciSparc Ltd. announces a reverse share split at a ratio of 1-for-26, resulting in approximately 521,090 Ordinary Shares issued and outstanding. The Company's shares will begin trading on Nasdaq Capital Market on a post-split basis on September 28, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3354.45%
Tags
none
News
SciSparc Announces 1-for-26 Reverse Share Split
Rhea-AI Summary
SciSparc Ltd. will conduct a reverse share split of its issued and outstanding ordinary shares at a ratio of 1-for-26. The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on September 28, 2023, under the Company's existing trading symbol 'SPRC'. Fractional shares will be rounded up to the nearest whole ordinary share. Per share exercise price and the number of shares issuable upon exercise of outstanding options or warrants will be adjusted proportionately.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
none
-
News
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
Rhea-AI Summary
SciSparc engages Rosario Capital to identify potential strategic transactions
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.71%
Tags
none
-
News
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
Rhea-AI Summary
SciSparc initiates Phase IIb Clinical Trial for SCI-110 in treating Tourette Syndrome at Tel Aviv Sourasky Medical Center. Positive results from Phase IIa study at Yale School of Medicine. Trial to evaluate efficacy, safety, and tolerability of SCI-110 in adult patients. Primary efficacy objective is tic severity change using Yale Global Tic Severity Scale. Trial conducted at three global centers of excellence. Institutional Review Board approvals secured. Israeli Ministry of Health and German Federal Institute for Drugs and Medical Devices approvals obtained.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
clinical trial
News
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
Rhea-AI Summary
SciSparc Ltd. receives additional 180-day compliance period from Nasdaq to regain compliance with minimum bid price rule.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
none
-
News
Aegis Capital Corp. acted as Sole Bookrunner on a $1.3 Million Underwritten Public Offering for SciSparc Ltd. (NASDAQ: SPRC)
Rhea-AI Summary
Aegis Capital Corp. served as the Sole Bookrunner for SciSparc Ltd.'s $1.3 million Underwritten Public Offering on NASDAQ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
offering
-
News
SciSparc Ltd. Closes $1.3 Million Underwritten Public Offering
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) announced the closing of a public offering, raising approximately $1.3 million in gross proceeds. The offering included 6,500,000 ordinary shares at $0.20 per share, with the intention to use the funds for working capital. Aegis Capital Corp. was granted a 45-day option to purchase up to an additional 975,000 ordinary shares. The offering is pursuant to an effective shelf registration statement on Form F-3. Interested parties can obtain more information from the SEC's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.41%
Tags
offering
News
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
Rhea-AI Summary
SciSparc Ltd. (SPRC) Announces Pricing of $1.3M Public Offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-62.83%
Tags
offering
Stock SPRC logo
SciSparc Ltd. Ordinary Shares

Nasdaq:SPRC

SPRC Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

SPRC Stock Data

3.35M
324.71k
0.02%
2.42%
6.6%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Tel Aviv